Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence;3-Phasen-PET/CT mit I8F-Fluorcholin zur Evaluation des Prostatakrebsrezidivs

NuklearMedizin

Volumn 48, Issue 1, 2009, Pages 1-9

  Steiner, C H ^a   Vees, H ^a   Zaidi, H ^a   Wissmeyer, M ^a   Berrebi, O ^a   Kossovsky, M R ^a   Khan, H G ^b   Miralbell, R ^a,c   Ratib, O ^a   Buchegger, F ^a,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Institut de Radiologie Jean Violette   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Inststuto Oncológico Teknon   (Spain)

Author keywords

3 phase pet ct; Prostote concer recurrence; Rising psa

Indexed keywords

FLUORINE 18; FLUOROCHOLINEFLUOROMETHYL DIMETHYL 2 HYDROXYETHYLAMMONIUM; RADIOISOTOPE; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUOROCHOLINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CANCER; BLOOD; CANCER STAGING; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIOGRAPHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCINTISCANNING; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 62549165172     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0194     Document Type: Article

References (38)

1. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34: 185-196.
2. 18F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008; 35: 246-252.
3. 18F]fluoro-2-deoxy-D-glucose. Int.1 Radiat Oncol Biol Phys 2004; 59: 1295-1300.
4. 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35: 1766-1774.
5. 18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33: 1387-1398.
6. Coakley FY Teh HS. Qayyum A et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233:441-448.
7. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997: 37: 1035- 1041.
8. Costouros NG, Coakley FY Westphalen AC et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2007: 188: 812-816.
9. 18F] fluoroeholine of pharmaceutical quality, Eur J Nucl Med Mol Imaging 2003; 30: S313.
10. Freedland SJ, Moul JW Prostate specific antigen recurrence after definitive therapv. J Urol 2007; 177: 1985-1991.
11. Freedland SJ, Sutter ME, Dorey F Aronson WJ, Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate- specific antigen. Urology 2003; 61: 365-369.
12. 11C-Choline PET/CT in patients treated with radical prostatectomy and PSA serum level increase: influence of PSA velocirty and PSA doubling time on PET detection rate. Eur J Nucl Med Mol Imaging 2008; 35(Suppl 2): S156.
13. 11C] Choline PET/CT uptake in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008: 35 (Suppl 2): S156.
14. 18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176: 2014-2018.
15. Harisinghani MG. Barentsz J, HahnPF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl J Med 2003; 348: 2491-2499.
16. Plorwitz EM, Thames HD, Kuban DA et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005; 173: 797-802.
17. 18F]-choline PET/CT for staging and restating of prostate cancer. Eur J Nucl Med Mol Imagmg 2008; 35: 253-263.
18. 11C] Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008: 35: 18-23.
19. 18F-flu- orocholine PET. J Nucl Med 2006; 47:262-269.
20. Malpica A, Matisic JP. Niekirk DV et al. Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologie issues. Gynecol Oncol 2005; 99: S38-S52.
21. Michel C. Sibomana M, Boi A et al. Preserving Poisson characteristics of PET data with weighted OSEM reconstruction Proc IEEE Nuclear Science Svmp and Medical Imaging Conf 1998: 2: 1323-1329.
22. Oehr P. Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol 2007; 19: 259-264.
23. Oyama N, Miller TR, Dehdashti F et al. 11 C-acet- ate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549-555.
24. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-280.
25. 11C]cho- line PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008: 35: 9-17.
26. 11C-choline PET/CT. J Nucl Med 2006; 47: 1249-1254.
27. 11 C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007; 99: 1421-1426.
28. Rousset OG, Rahmim A, Alavi A. Zaidi H. Strategies for partial volume correction in PET. PET Clin 2007; 2: 235-249.
29. Schmid DT, John FL Zweifel R et al. Fluorocho- line PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623-628.
30. 18F-fluorocyclobutane-1 -carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48: 56-63.
31. Siegel C. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. J Urol 2005; 174: 569.
32. 11C] choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004: 31 : 317-324.
33. 11C-choline PET/CT. Radiology 2007; 244: 797-806.
34. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy; BJU Int 2007;99:1415-1420.
35. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging inpatients with recurrent prostate cancer. J Clin Oncol 2006; 24: 2513-2519.
36. Ward JF, Moul JW Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 2005; 15: 181-186.
37. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005; 173: 1156-1160.
38. Weckerman D, Dorn R, Trefz M et al. Sentinel lymph node dissection for prostate cancencxperi- ence with more than 1000 patients. J Urol 2007; 177:916-920.